Impact of adjuvant chemotherapy in the long-term outcome of patients with resected gastric cancer

Journal of Surgical Oncology

Volumn 82, Issue 4, 2003, Pages 234-240

  Grau, Juan J ^a   Martín, Marta ^a   Fuster, José ^a   Pera, Manuel ^a   García Valdecasas, Juan C ^a   Bombí, Josep A ^a   Bordas, José M ^a   Alcobendas, Felipe ^a   Grande, Luis ^a   Estapé, Jordi ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Adjuvant chemotherapy; Gastric cancer; Mitomycin C; Prognosis; Tegafur

Indexed keywords

MITOMYCIN C; TEGAFUR;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GASTRECTOMY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; STOMACH ADENOCARCINOMA; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TEGAFUR; TREATMENT OUTCOME;

EID: 12244249161     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.10217     Document Type: Article

References (29)

1. Grau JJ, Estapé J, Fuster J, et al.: Randomized trial of adjuvant chemotherapy with mitomycin plus Torafur versus mitomycin alone in resected locally advanced gastric cancer. J Clin Oncol 1998;16:1036-1039.
2. Alcobendas F, Milla A, Estapé J, et al.; Mitomycin C as an adjuvant in resected gastric cancer. Ann Surg 1983;198:13-17.
3. Estapé J, Grau JJ, Alcobendas F, et al.: Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10 year follow-up. Ann Surg 1991;213:219-221.
4. Grau JJ, Estapé J, Alcobendas F, et al.: Positive results of adjuvant mitomycin-C in resected gastric cancer: A randomised trial on 134 patients. Eur J Cancer 1993;29A:340-342.
5. Cirera L, Balil A, Batiste E, et al.: Efficacy of adjuvant mitomycin C plus Tegafur in stage III gastric cancer. Proc ASCO 1997;16: 278a.
6. Cirera L, Balil A, Batiste-Alentorn E, et al.: Randomized clinical trial of adjuvant Mitomycin plus Tegafur in patients with resected stage III gastric cancer. J Clin Oncol 1999;17:3810-3815.
7. American Joint Committe on Cancer. Manual for staging of cancer. 3rd edn. Philadelphia: J.B. Lippincott. 1988.
8. Lessene JB, Rothchild N, Erikson B, et al.: Cancer-associated hemolytic-uremic syndrome: Analysis of 85 cases from a National registry. J Clin Oncol 1989;7:781-789.
9. Peto R, Pike MC, Armitage P, et al.: Design and analysis of randomized clinical trials requiring prolonged observations on each patient. Br J Cancer 1976;34:585-612.
10. Kaplan EL, Meier P: Nonparametric estimations from incomplete observations. Am Stat Assoc 1958;53:457-463.
11. 2 in the log-rank test for survival data on tumor incidence data. Biometrics 1973;29:279-286.
12. Cox DR: Regression models and life-tables. J R Stat Soc 1972; 34:187-220.
13. Miller AB, Hoogstraten B, Staquet M, et al.: Reporting results of cancer treatment. Cancer 1981;47:207-214.
14. Schwartz G: Invasion and metastases in gastric cancer: In vivo models with clinical correlations. Semin Oncol 1996;23:316-324.
15. Moertel CG, Fleming TR, Macdonald JS, et al.: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 1995;22:321-326.
16. Bonadonna G, Valagusa P, Moliterni A, et al.: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up. N Eng J Med 1995;332:901-906.
17. Fukushima M: Adjuvant therapy of gastric cancer: The Japanese experience. Semin Oncol 1996;23:369-378.
18. Bunt AMG, Hermans J, Smit VTHBM, et al.: Sugical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J Clin Oncol 1995;13: 19-25.
19. Hermans J, Bonenkamp JJ, Boon MC, et al.: Adjuvant therapy after curative resection for gastric cancer: Meta-analysis of randomized trials. J Clin Oncol 1993;11:1441-1447.
20. Pignon JP, Ducreux M, Rougier P: Meta-analysis of adjuvant chemotherapy in gastric cancer: a critical reappraisal. J Clin Oncol 1994;12:877-878.
21. Hermans J, Bonenkamp H: In reply (letter). J Clin Oncol 1994; 12:879-880.
22. Earle CC, Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-asian patients: Revisiting a meta-analysis of randomized trials. Eur J Cancer 1999;35:1059-1064.
23. Nakajima T, Nashimoto A, Kitamura M, et al.: Adjuvant mitomycin and fluorouracil followed by oral uracil plus Tegafur in serosa-negative gastric cancer: A randomised trial. Lancet 1999; 354:273-277.
24. Giaretti W, Danova M, Geido E, et al.: Flow cytometric DNA index in the prognosis of colorectal cancer. Cancer 67:1921-1925.
25. Elsaleh H, Joshep D, Grieu F, et al.: Association of tumor site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000;355:1745-1750.
26. Dhar DK, Kubota H, Tachivana M, et al.: Body mass index determines the success of lymph node dissection and predicts the outcome odf gastric carcinoma patients. Oncology 2000;59:8-23.
27. Maehara Y, Tomoda M, Hasuda S, et al.: Prognostic value of p53 protein expresion for patients with gastric cancer - A multivariate analysis. Br J Cancer 1999;79:1255-1261.
28. Macdonald JS, Smalley S, Benedetti J, et al.: Postoperative combined radiation and chemotherapy improves disease-free survival and overall survival in resected adenocarcinoma of the stomach and G.E. junction. Results of Intergroup study INT-016 (SWOG9008). Proc ASCO 2000;19:1.
29. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach of gastroesophageal junction. N Eng J Med 2001;345:725-730.